Prevention of Diverticulitis by Taking a Daily Probiotic
Launched by UNIVERSITY OF SURREY · May 31, 2012
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
Because dietary fibre, obesity and diabetes are all confounding factors that influence the frequency and severity of attacks of diverticulitis, the research project will take account of this by:
1. Monitoring dietary fibre using a diet diary
2. Measurement of height and weight to determine BMI
3. Screening for undiagnosed diabetes and pre-diabetes
As well as keeping a diet diary, subjects will be asked to keep a general health diary, and to complete gut health questionnaires at start, 6 months and 12 months.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. A history of two episodes of UAD treated with antibiotics in the last five years.
- • 2. Diverticulosis confirmed by colonoscopy, barium enema, USS, CT or MRI imaging or at surgery.
- • 3. Agreement to consume one bottle of Yakult daily for 12 months
- • 4. Availability of space in the domestic refrigerator for storage of Yakult units
- • 5. Able to access depot (local primary care premises or chemist) to collect regular supplies of Yakult
- • 6. Able to cope with keeping a diary etc.
- • 7. Willing to take Yakult supplies and a cold bag on holiday to ensure as near as possible continuous daily doses (certainly never more than one week break as Lactobacilli casei will persist in the human gut for at least one week
- • 8. Capable of giving informed consent
- • 9. Aged ≥ 50 and ≤ 75 years at commencement of trial.
- Exclusion Criteria:
- • 1. Recent history of peptic ulcer
- • 2. Chronic renal insufficiency
- • 3. Ongoing or past major diverticulitis complications
- • 4. Any serious debilitating illness (cancers, cardiovascular disease etc. but not DM)
- • 5. Dementias or memory problems
- • 6. Regular probiotic consumption over the past year.
- • 7. Undergoing immunosuppressive therapy or treatment
- • 8. Lactose intolerance or intolerance to dairy products
- • 9. Immunosuppressed patients
About University Of Surrey
The University of Surrey is a leading research institution located in the United Kingdom, renowned for its commitment to advancing knowledge and improving health outcomes through innovative clinical research. With a strong emphasis on multidisciplinary collaboration, the university fosters an environment that encourages cutting-edge studies across various fields, including medicine, health sciences, and technology. The University of Surrey actively engages in clinical trials aimed at exploring new therapeutic approaches, enhancing patient care, and contributing to the global body of medical knowledge. Its state-of-the-art facilities and expertise in clinical research methodology ensure rigorous study design and ethical standards, making it a valuable partner in the pursuit of scientific excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guildford, Surrey, United Kingdom
Patients applied
Trial Officials
Simon de Lusignan, MB ChB
Study Director
University of Surrey
John AA Nichols, MB ChB
Principal Investigator
University of Surrey
Michelle Gibbs, BSc PhD
Study Director
University of Surrey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials